Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | recruiting | Phase 1 | 675 | GlaxoSmithKlineINDUSTRY | 15 | Jun 25, 2026 | clinicaltrials |
| NCT06952010 | A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 303 | ExelixisINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07060989 | A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation(NTS071) | recruiting | Phase 1 / Phase 2 | 220 | Nutshell Therapeutics (Shanghai) Co., LTD.INDUSTRY | 2 | Jun 24, 2026 | clinicaltrials |
| NCT04678648 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | recruiting | Phase 1 | 134 | RasCal Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | SanofiINDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT05684965 | XTX301 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 358 | Xilio Development, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 233 | Ensem TherapeuticsINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT05434234 | A Study of YL201 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 6 | Jun 22, 2026 | clinicaltrials |
| NCT05694715 | Combination Therapy in Cancers With Mutations in DNA Repair Genes | recruiting | Phase 1 | 24 | University of California, San FranciscoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06992713 | A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656116 | Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors | recruiting | Phase 1 | 27 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06636435 | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | recruiting | Phase 1 | 66 | Chiome Bioscience Inc.INDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06297525 | Study of STP938 (Dencatistat) in Advanced Solid Tumours | recruiting | Phase 1 | 70 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT05768932 | BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 260 | SillaJen, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Eikon TherapeuticsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT07019779 | Study of CM518D1 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 375 | BioNTech SEINDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT07638371 | FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648472 | A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours. | recruiting | Phase 1 | 18 | Joint Biosciences Ltd.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07284186 | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 155 | Plexium, Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07348653 | A Study of MG2512 Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 116 | Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT07163325 | EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | recruiting | Phase 1 | 48 | Epics TherapeuticsINDUSTRY | 4 | Jun 11, 2026 | clinicaltrials |
| NCT05521984 | Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | recruiting | Phase 1 | 448 | Alterome Therapeutics, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06975410 | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Yuhan CorporationINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639047 | An Initial Evaluation of AN8025 in Solid Tumors | recruiting | Phase 1 | 91 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04890613 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | recruiting | Phase 1 | 52 | Senhwa Biosciences, Inc.INDUSTRY | 2 | Jun 8, 2026 | clinicaltrials |
| NCT07238075 | ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers | recruiting | Phase 1 | 290 | Adcytherix SASINDUSTRY | 2 | Jun 8, 2026 | clinicaltrials |
| NCT07252479 | Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | recruiting | Phase 1 | 118 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07512583 | Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 178 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07570563 | Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. | recruiting | Phase 1 / Phase 2 | 24 | Chinese PLA General HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05232409 | Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer | recruiting | Phase 1 | 72 | Valley Health SystemOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06554795 | First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | DualityBio Inc.INDUSTRY | 3 | Jun 5, 2026 | clinicaltrials |
| NCT06894745 | PET [89Zr]DFO-starPEG in Solid Tumors | recruiting | Phase 1 | 13 | Robert Flavell, MD, PhDOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04621435 | Imaging of Solid Tumors Using FAP-2286 | recruiting | Phase 1 | 191 | Thomas HopeOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05004116 | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | recruiting | Phase 1 / Phase 2 | 77 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06480552 | An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 240 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | recruiting | Phase 1 | 604 | Revolution Medicines, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07077434 | A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 32 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 3, 2026 | clinicaltrials |
| NCT07086768 | Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 57 | Lei ZhengOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623850 | A Phase I Study of JLM019 Injection(JLM019) | recruiting | Phase 1 | 115 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04796012 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06815575 | A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours. | recruiting | Phase 1 | 53 | Racura Oncology LtdINDUSTRY | 3 | Jun 2, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 25, 2026source: clinicaltrials